# Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors

> **NCT04517539** · PHASE2 · UNKNOWN · sponsor: **Shanghai Cancer Hospital, China** · enrollment: 65 (estimated)

## Conditions studied

- Thymic Epithelial Tumor

## Interventions

- **DRUG:** rhGM-CSF，Peginterferon alfa-b2，radiation

## Key facts

- **NCT ID:** NCT04517539
- **Lead sponsor:** Shanghai Cancer Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-10
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2020-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04517539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04517539, "Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04517539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*